SCHEMBL3166444

SCHEMBL3166444

Cc1ccc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)cc1C(F)(F)F

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.68
BRAF P15056 2/20 0.65
MAPK14 Q16539 2/20 0.65
TNNI3K Q59H18 2/20 0.65
CDK8 P49336 3/20 0.64
SRC P12931 2/20 0.62
RAF1 P04049 12/20 0.59
RIPK2 O43353 2/20 0.56
MEN1 O00255 1/20 0.56
PLK4 O00444 1/20 0.56
CIT O14578 1/20 0.56
AURKA O14965 1/20 0.56
MUSK O15146 1/20 0.56
EPHB6 O15197 1/20 0.56
MAPK13 O15264 1/20 0.56
MLNR O43193 1/20 0.56
MAP3K7 O43318 1/20 0.56
DYRK3 O43781 1/20 0.56
PDE6D O43924 1/20 0.56
NR1I2 O75469 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL939171 0.86 CDK8 (0.70) KDRBRAFMAPK14TNNI3KCDK8
SCHEMBL5568335 0.86 KDR (0.67) KDRBRAFMAPK14TNNI3KCDK8
SCHEMBL30462521 0.85 RAF1 (0.73) KDRBRAFMAPK14TNNI3KCDK8
SCHEMBL3181311 0.85 RAF1 (0.70) KDRBRAFMAPK14TNNI3KCDK8
SCHEMBL936533 0.85 RAF1 (0.73) KDRBRAFMAPK14TNNI3KCDK8
SCHEMBL12795164 0.85 KDR (0.67) KDRBRAFMAPK14TNNI3KCDK8
SCHEMBL13885368 0.84 RAF1 (0.80) KDRBRAFMAPK14TNNI3KCDK8
SCHEMBL29045853 0.83 RAF1 (0.70) KDRBRAFMAPK14TNNI3KCDK8
SCHEMBL13528808 0.82 SRC (0.59) KDRBRAFMAPK14TNNI3KCDK8
SCHEMBL16907654 0.81 KDR (1.00) KDRBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652022-B2 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; NOVARTIS AG (CH) 2010-01-26 US disclosed
US-7652022-B2 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; NOVARTIS AG (CH) 2010-01-26 US disclosed
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases FLOERSHEIMER ANDREAS 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases UCK2, PRKDC, PRKACA KDR 3898/4885BRAF 284/4885MAPK14 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.